PH27172A - Fertility control - Google Patents

Fertility control Download PDF

Info

Publication number
PH27172A
PH27172A PH35702A PH35702A PH27172A PH 27172 A PH27172 A PH 27172A PH 35702 A PH35702 A PH 35702A PH 35702 A PH35702 A PH 35702A PH 27172 A PH27172 A PH 27172A
Authority
PH
Philippines
Prior art keywords
paf
embryo
antagonist
sri
faf
Prior art date
Application number
PH35702A
Other languages
English (en)
Inventor
Christopher O Neill
Original Assignee
North Sydney Area Health Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Sydney Area Health Serv filed Critical North Sydney Area Health Serv
Publication of PH27172A publication Critical patent/PH27172A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH35702A 1986-08-22 1987-08-20 Fertility control PH27172A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPH764286 1986-08-22

Publications (1)

Publication Number Publication Date
PH27172A true PH27172A (en) 1993-04-02

Family

ID=3771782

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35702A PH27172A (en) 1986-08-22 1987-08-20 Fertility control

Country Status (8)

Country Link
US (1) US4879285A (de)
EP (1) EP0261798A3 (de)
JP (1) JPS63115819A (de)
KR (1) KR880002544A (de)
DK (1) DK431587A (de)
NZ (1) NZ221518A (de)
PH (1) PH27172A (de)
ZA (1) ZA876215B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5263848A (en) * 1986-11-24 1993-11-23 Canadian Occidental Petroleum, Ltd. Preparation of oil-in-aqueous phase emulsion and removing contaminants by burning
DK0454429T3 (da) * 1990-04-27 1997-03-17 R Tech Ueno Ltd Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
CA2075300A1 (en) * 1990-12-04 1992-06-05 Mount Sinai School Of Medicine Of The City University Of New York Therapeutic and diagnostic applications of fetal fibronectin
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
WO1997007813A1 (en) * 1995-08-28 1997-03-06 Toray Industries, Inc. Fertility agent
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
CN1871341A (zh) * 2003-08-20 2006-11-29 悉尼北方和中部海岸区医疗服务系统 提高胚胎生存力的方法
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
JP2011032289A (ja) * 2010-11-17 2011-02-17 Maruzen Pharmaceut Co Ltd エストロゲン作用剤および皮膚化粧料
KR101360830B1 (ko) * 2013-11-21 2014-02-11 (주)나비바이오텍 젖산을 함유한 동물의 난소 기능 불활 조성물
KR102048205B1 (ko) * 2016-12-20 2019-11-25 성신여자대학교 연구 산학협력단 분비 백혈구 단백질분해효소 억제제를 포함하는 포유동물 초기 배아 성장 배양액 조성물 및 이를 이용한 정상 발생 속도 유지를 위한 포유동물 초기 배아의 체외 배양방법
HU231212B1 (hu) * 2018-04-16 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás iloprost előállítására

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883304A (en) * 1972-05-25 1975-05-13 Conifer Lab Method for testing pregnancy
US4543339A (en) * 1982-03-16 1985-09-24 Oneill Christopher Early pregnancy detection by detecting enhanced blood platelet activation
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
US4540709A (en) * 1983-10-13 1985-09-10 Merck & Co., Inc. Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran
US4539332A (en) * 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
US4610687A (en) * 1984-08-06 1986-09-09 Board Of Trustees Operating Michigan State University Method for breeding control in female bovines
US4665096A (en) * 1985-07-11 1987-05-12 Oraa Espartaco Contraceptive methods and compositions
US4619917A (en) * 1985-07-18 1986-10-28 Sandoz Pharm. Corp. Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts
US4704462A (en) * 1985-08-22 1987-11-03 Merck & Co., Inc. Substituted 2,3,3a,6-tetrahydro-6-oxobenzofuran derivative useful as PAF antagonist

Also Published As

Publication number Publication date
ZA876215B (en) 1988-02-23
JPS63115819A (ja) 1988-05-20
KR880002544A (ko) 1988-05-09
EP0261798A3 (de) 1990-05-09
NZ221518A (en) 1990-07-26
DK431587D0 (da) 1987-08-19
DK431587A (da) 1988-02-23
US4879285A (en) 1989-11-07
EP0261798A2 (de) 1988-03-30

Similar Documents

Publication Publication Date Title
MORISHIGE et al. Temporal aspects of the regulation of corpus luteum function by luteinizing hormone, prolactin and placental luteotrophin during the first half of pregnancy in the rat
Harper Platelet-activating factor: a paracrine factor in preimplantation stages of reproduction?
Lau et al. Pregnancy blockade by indomethacin, an inhibitor of prostaglandin synthesis: its reversal by prostaglandins and progesterone in mice
PH27172A (en) Fertility control
Pratt et al. Induced corpora lutea in the postpartum beef cow. I. Comparison of gonadotropin releasing hormone and human chorionic gonadotropin and effects of progestogen and estrogen
KR20010093276A (ko) 불임증 치료
JP2021522268A (ja) 制御された卵巣刺激のための組成物
Peters Hormonal control of the bovine oestrous cycle. I. The natural cycle
Labhsetwar Effects of prostaglandin F2α on some reproductive processes of hamsters and rats
Johnson et al. Epidermal growth factor (EGF) replaces estradiol for the initiation of embryo implantation in the hypophysectomized rat
Nutting et al. Effects of prostaglandins on fertility in female rats
US5610138A (en) Process for treating infertility and an agent for use in the process
Cha et al. Viability of human follicular oocytes collected from unstimulated ovaries and matured and fertilized in vitro
El-Banna The degenerative effect on rabbit implantation sites by indomethacin. I. Timing of indomethacin action, possible effect on uterine proteins and the effect of replacement doses of PGF2α
Labhsetwar Prostaglandin E2: Analysis of effects on pregnancy and corpus luteum in hamsters and rats
Labhsetwar Prostaglandin E1: studies on antifertility and luteolytic effects in hamsters and rats
Clemens et al. Termination of pregnancy in rats by a prolactin implant in median eminence
Webley et al. Changing responsiveness of luteal cells of the marmoset monkey (Callithrix jacchus) to luteotrophic and luteolytic agents during normal and conception cycles
Goldsmith et al. A histochemical and histological study of the effects of cortisone on the lower incisors of fetal and post-natal rats
AU608530B2 (en) Fertility control
Hafez Endocrine control of reception, transport, development and loss of rabbit ova
Critser et al. Effect of indomethacin on the interestrous interval of intact and hysterectomized pseudopregnant mice
Persaud Reproductive and teratological studies with prostaglandins
Weems et al. In vivo progestin treatments inhibit nitric oxide and endothelin-1-induced bovine endometrial prostaglandin (PG) E (PGE) secretion in vitro
US20240358799A1 (en) Methods and compositions for reproductive management of sheep and goats